Weber A, Bounameaux H
Department of Medicine, University Hospital of Geneva, Switzerland.
J Cardiovasc Pharmacol. 1990 May;15(5):853-5. doi: 10.1097/00005344-199005000-00023.
The effects of 5 mg sublingual nifedipine on a standardized cold provocation test were compared with that of placebo in a double-blind, cross-over trial in 10 patients with Raynaud's disease. The percentage decrease of finger systolic pressure in the cooled finger (as compared with the contralateral control finger) was significantly lower at 10 degrees C (p less than 0.02) and 15 degrees C (p less than 0.05) after nifedipine than after placebo. These improved digital pressure values on cooling were associated with a decreased systolic blood pressure (SBP) from 131.2 (SD 10.8) to 126.2 (SD 10.1) mm Hg (p less than 0.001) and an increased heart rate (HR) from 65.5 (SD 16.1) to 69.6 (SD 16.7) beats/min (p less than 0.002) but without significant changes in diastolic blood pressure (DBP), digital blood flow (BF), or peripheral vascular resistance (PVR) in cutaneous vascular bed. Three patients experienced headache under nifedipine, but this side effect was disagreeable in only one case. These data suggest using low-dose nifedipine (5 mg sublingually) 15-30 min before predictable cold exposure and Raynaud's phenomenon. Such a procedure might be more effective and safer than chronic intake of higher doses of nifedipine, as currently recommended in Raynaud's attacks.
在一项双盲、交叉试验中,对10例雷诺病患者比较了5毫克舌下含服硝苯地平与安慰剂对标准化冷激发试验的影响。硝苯地平组在10摄氏度(p<0.02)和15摄氏度(p<0.05)时,冷却手指的收缩压下降百分比(与对侧对照手指相比)显著低于安慰剂组。这些冷却时改善的指压值与收缩压(SBP)从131.2(标准差10.8)降至126.2(标准差10.1)毫米汞柱(p<0.001)以及心率(HR)从65.5(标准差16.1)升至69.6(标准差16.7)次/分钟(p<0.002)相关,但皮肤血管床的舒张压(DBP)、指血流量(BF)或外周血管阻力(PVR)无显著变化。3例患者在硝苯地平治疗下出现头痛,但只有1例患者觉得这种副作用令人不适。这些数据表明,在可预测的寒冷暴露和雷诺现象发生前15 - 30分钟舌下含服低剂量硝苯地平(5毫克)。这种方法可能比目前雷诺发作时推荐的长期服用高剂量硝苯地平更有效、更安全。